Brokerages Set Phreesia, Inc. (NYSE:PHR) PT at $29.42

Shares of Phreesia, Inc. (NYSE:PHR - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twelve analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $29.42.

Several analysts recently issued reports on the company. Canaccord Genuity Group reiterated a "buy" rating and set a $34.00 target price on shares of Phreesia in a report on Thursday, September 5th. KeyCorp dropped their target price on Phreesia from $27.00 to $25.00 and set an "overweight" rating on the stock in a report on Thursday, July 11th. Robert W. Baird upped their target price on Phreesia from $31.00 to $34.00 and gave the stock an "outperform" rating in a report on Friday, September 6th. DA Davidson reiterated a "buy" rating and set a $32.00 target price on shares of Phreesia in a report on Thursday, September 5th. Finally, JPMorgan Chase & Co. boosted their price target on Phreesia from $27.00 to $28.00 and gave the stock an "overweight" rating in a research report on Monday, September 9th.

Phreesia Stock Up 1.0 %

Shares of Phreesia stock traded up $0.18 during trading on Friday, reaching $18.47. The stock had a trading volume of 241,118 shares, compared to its average volume of 338,121. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -10.26 and a beta of 0.95. The stock has a fifty day moving average price of $22.19 and a two-hundred day moving average price of $22.11. Phreesia has a 52 week low of $14.17 and a 52 week high of $29.16. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.03.

Phreesia (NYSE:PHR - Get Free Report) last released its earnings results on Wednesday, September 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.06. Phreesia had a negative return on equity of 39.34% and a negative net margin of 25.73%. The business had revenue of $102.12 million for the quarter, compared to analyst estimates of $101.76 million. Sell-side analysts predict that Phreesia will post -1.23 EPS for the current fiscal year.

Insider Activity

In other news, General Counsel Allison C. Hoffman sold 14,110 shares of the company's stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $26.03, for a total value of $367,283.30. Following the transaction, the general counsel now owns 121,003 shares of the company's stock, valued at approximately $3,149,708.09. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Balaji Gandhi sold 3,502 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $23.25, for a total transaction of $81,421.50. Following the sale, the chief financial officer now owns 98,578 shares of the company's stock, valued at $2,291,938.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Allison C. Hoffman sold 14,110 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $26.03, for a total value of $367,283.30. Following the sale, the general counsel now directly owns 121,003 shares in the company, valued at $3,149,708.09. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 44,107 shares of company stock valued at $1,035,226. 5.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Phreesia

A number of large investors have recently added to or reduced their stakes in the stock. Trust Point Inc. grew its position in Phreesia by 3.5% during the third quarter. Trust Point Inc. now owns 17,887 shares of the company's stock worth $408,000 after buying an additional 607 shares in the last quarter. Ensign Peak Advisors Inc grew its position in Phreesia by 3.2% during the second quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company's stock worth $477,000 after buying an additional 700 shares in the last quarter. ProShare Advisors LLC grew its position in Phreesia by 8.6% during the first quarter. ProShare Advisors LLC now owns 9,522 shares of the company's stock worth $228,000 after buying an additional 751 shares in the last quarter. Rhumbline Advisers grew its position in Phreesia by 1.0% during the second quarter. Rhumbline Advisers now owns 82,136 shares of the company's stock worth $1,741,000 after buying an additional 853 shares in the last quarter. Finally, Swiss National Bank grew its position in Phreesia by 1.0% during the first quarter. Swiss National Bank now owns 104,300 shares of the company's stock worth $2,496,000 after buying an additional 1,000 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company's stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.